Story thread · 3 reports / 2 sources
AbbVie touts strong momentum for Skyrizi despite rising competition
endpts.com · 11d
How the coverage leans
Across 2 sources · syndicated copies counted once
If AbbVie executives are bothered by growing threats to their immunology powerhouse, they aren't letting on. Earlier this year, analysts were pondering how the company’s blockbuster Skyrizi might fare against competition from ...
First report: AbbVie wins EU clearance for Rinvoq as first systemic treatment for non-segmental vitiligo — seekingalpha.com, 13d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.